ClinicalTrials.gg
CompletedNCT02301156GENUINEUpdated May 20, 2022Results posted

Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)

A Phase 3 interventional study of Ublituximab and Ibrutinib in Chronic Lymphocytic Leukemia, sponsored by TG Therapeutics, Inc.. Completed at 88 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-05-20.

Sponsored by TG Therapeutics, Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell — none open to participants now, 1 under way, none of them phase 3. ublituximab · Leukemia, Lymphocytic, Chronic, B-Cell.

Enrollment
4th of 13
126 · median 51
Started
2015
with 1 other
Phase 3
2 of 13
none open now
Registered
6th of 13
by date
Lead sponsor
10 of 13
TG Therapeutics, Inc.

Among the 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell, this one is the 4th largest by enrollment, is one of 2 that started in 2015, is one of 2 in phase 3, and was the 6th registered.

Leukemia, Lymphocytic, Chronic, B-Cell

2,036 studies on the registry are indexed under Leukemia, Lymphocytic, Chronic, B-Cell; 236 are open to participants now.

Browse Leukemia, Lymphocytic, Chronic, B-Cell studies →

Open to participants now

None of the 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell is open now. The open studies under Leukemia, Lymphocytic, Chronic, B-Cell, anywhere →

About ublituximab

ublituximab: first FDA approval 2022 (BRIUMVI), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 187 Leukemia, Lymphocytic, Chronic, B-Cell studies recruiting now, 150 (80%) set no upper age limit and 15 (8%) stop at 75 or younger; 17 take children under 18; 12 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 13 studies testing ublituximab in Leukemia, Lymphocytic, Chronic, B-Cell as a file.
02

Study summary

This study evaluates the effect of the addition of ublituximab, a novel monoclonal antibody, to ibrutinib compared to ibrutinib alone on antitumor activity, as measured by the overall response rate (ORR = CR [complete response] + PR [partial response]) in previously treated Chronic Lymphocytic Leukemia (CLL) participants with high-risk cytogenetic features. Half of the participants will receive ublituximab in combination with ibrutinib, while the other half will receive ibrutinib alone.

03

Conditions studied

  • Chronic Lymphocytic Leukemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Previously treated Chronic Lymphocytic Leukemia (CLL) requiring treatment
  • At least one high-risk cytogenetic feature defined by the presence of 17p deletion, 11q deletion and/or p53 mutation
  • (ECOG) score of 0 to 2

Exclusion criteria

Exclusion Criteria:

  • Any major surgery, chemotherapy or immunotherapy within the last 21 days
  • Evidence of virus, virus or known (HIV) infection
  • Autologous hematologic stem cell transplant within 3 months of study entry. Prior Allogeneic hematologic stem cell transplant is excluded
  • Transformation of CLL to aggressive Non-Hodgkin's Lymphoma (NHL) (Richter's transformation)
  • Previous therapy with ibrutinib, or any drug that specifically inhibits Bruton's tyrosine kinase (BTK)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
126 participants (actual)

Study arms

  • Experimental
    Ublituximab + Ibrutinib

    Participants will receive ublituximab intravenous (IV) infusion, up to 150 milligrams (mg) once on Day 1, 750 mg on Day 2, 900 mg on Days 8 and 15 of Cycle 1 (Cycle duration=28 days) followed by 900 mg on Day 1 of Cycles 2 to 6 and 900 mg on Day 1 of every 3rd cycle thereafter for up to 62 months along with ibrutinib 420 mg capsules, orally, once daily (QD) in each 28-day cycle for up to 62 months.

    Drug: Ublituximab · Drug: Ibrutinib

  • Active comparator
    Ibrutinib

    Participants will receive ibrutinib 420 mg capsules, orally, QD in each 28-day cycle up to 62 months.

    Drug: Ibrutinib

Interventions

  • Administered as an IV infusion

    Also known as: TG-1101

  • Administered orally

    Also known as: IMBRUVICA

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    ORR: Percentage of participants with best overall response of partial response(PR) and complete response(CR). CR criteria: No evidence of new disease; Absolute lymphocyte count(ALC)\<4x10\^9/liter(L); Regression of all target nodal masses to ≤1.5 centimeters(cm) in longest diameter(LD); Normal spleen,liver size; Regression to normal of all nodal non-target disease and disappearance of all detectable; Non-nodal, non-target disease; Morphologically negative bone marrow; No lymphoid nodules; Absolute neutrophil count(ANC)\>1.5x10\^9/L,platelets≥100x10\^9/L,hemoglobin (Hgb)≥110 gram per liter(g/L). PR criteria: No evidence of new disease; Response in 2 of following if abnormal at baseline: ALC\<4x10\^9/L or \>=50% decrease from baseline in sum of products(SPD) of target nodal lesions; splenomegaly; hepatomegaly;\>=50% decrease from baseline in CLL marrow infiltrate/B-lymphoid nodules; response in any 1:ANC\>1.5x10\^9/L,platelets\>100x10\^9/L,Hgb\>110g/L or \>=50% increase over baseline in any of these.

    Time frame: Up to 62 months

Secondary outcomes

  1. Complete Response (CR) Rate

    The CR rate was defined as the percentage of participants who achieved CR. CR criteria: No evidence of new disease; ALC \<4 x 10\^9/L; Regression of all target nodal masses to normal size ≤1.5 cm in the LD; Normal spleen and liver size; Regression to normal of all nodal non-target disease and disappearance of all detectable; Non-nodal, non-target disease; Morphologically negative bone marrow; No lymphoid nodules; ANC \>1.5 x 10\^9/L, platelets ≥100 x 10\^9/L, Hgb ≥110 g/L.

    Time frame: Up to 62 months

  2. Minimum Residual Disease (MRD) Negativity Rate

    MRD negativity rate was defined as the percentage of participants who were MRD negative post-baseline. If a participant was determined to be MRD negative by peripheral blood, a bone marrow aspirate was obtained to assess MRD in the bone marrow.

    Time frame: Up to 62 months

  3. Progression-Free Survival (PFS)

    PFS was defined as the time from the date of randomization until the date of first documentation of definitive disease progression (PD) or date of death from any cause, whichever occurs first. PD requires at least one of the following: New nodes \>1.5 cm in the LD and \>1.0 in longest perpendicular diameter (LPD), new or recurrent hepatomegaly or splenomegaly, new or reappearance of an unequivocal extra-nodal lesion, ≥50% increase from the nadir in the sum of products of target lesions, ≥50% increase in the LD of an individual node or extra-nodal mass, splenic/hepatic enlargement of ≥50% from nadir, unequivocal increase in the size of non-target disease, transformation to a more aggressive histology, decrease in platelet count or Hgb, \>50% decrease from the highest on-study platelet count, \>20 g/L decrease from the highest on-study Hgb.

    Time frame: From the randomization until the first documentation of PD or death whichever occurs first or up to 62 months

  4. Duration of Response (DOR)

    DOR:Interval from first documentation of CR/PR to first documentation of PD or death from any cause.CR:ALC\<4x10\^9/L;Regression to normal of target nodal masses,nodal non-target disease,and no detectable non-nodal,non-target disease;Normal spleen,liver size;Morphologically negative bone marrow,No lymphoid nodules;ANC\>1.5x10\^9/L,Platelets≥100x10\^9/L,Hgb≥110 g/L.PR:Response in 2 or more:ALC\<4x10\^9/L,\>=50% drop from baseline in ALC or SPD of target nodal lesions,Hepatosplenomegaly,\>=50% decrease from baseline in CLL marrow infiltrate/B-lymphoid nodules;Response in 1 or more:ANC\>1.5x10\^9/L,Platelets\>100x10\^9/L,Hgb\>110 g/L or \>=50% increase over baseline in any.PD:Response in 1 or more:new nodes,Hepatosplenomegaly,unequivocal extra-nodal lesion;≥50% increase from nadir in SPD of target lesions or LD of node/extra-nodal mass or Splenic/Hepatic size,Unequivocal increase in non-target disease,More aggressive histology;Drop of \>50% in platelets/\>20g/L in Hgb from highest on-study count.

    Time frame: From the first dose of study drug until the first documentation of PD or death whichever occurs first or up to 62 months

  5. Time to Response (TTR)

    TTR was defined as the interval from the randomization to the first documentation of CR or PR. CR criteria: No evidence of new disease; ALC \<4 x 10\^9/L; Regression of all target nodal masses to normal size ≤1.5 cm in the LD; Normal spleen and liver size; Regression to normal of all nodal non-target disease and disappearance of all detectable; Non-nodal, non-target disease; Morphologically negative bone marrow; No lymphoid nodules; ANC \>1.5 x 10\^9/L, platelets ≥100 x 10\^9/L, Hgb ≥110 g/L. PR criteria: No evidence of new disease; Response in 2 of following when abnormal at baseline: ALC\<4 x 10\^9/L or \>=50% decrease from baseline in SPD of target nodal lesions; splenomegaly; hepatomegaly; \>=50% decrease from baseline in CLL marrow infiltrate/B-lymphoid nodules; and Response in 1 of the following: ANC\>1.5 x 10\^9/L, platelets\>100 x 10\^9/L, Hgb\>110 g/L or \>=50% increase over baseline in any of these.

    Time frame: From the randomization up to 62 months

  6. Percentage of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)

    An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is any AE that occur after first dosing of study medication and through the end of the study or through 30 days after the last dose of study treatment, or is considered treatment-related regardless of the start date of the event, or is present before first dosing of study medication but worsens in intensity or the investigator subsequently considers treatment-related.

    Time frame: From the first dose up to 30 days after the last dose of study drug (up to 57.3 months)

07

Results

Posted May 20, 2022

Participant flow

A total of 126 participants were enrolled at investigative sites in Israel and the United States (US) from 27 January 2015 to 01 April 2020.

Participant flow — Overall Study
MilestoneUblituximab + IbrutinibIbrutinib
Started6462
Intent to treat (itt) population6462
Safety population5958
Completed1110
Not completed5352
Withdrew: Adverse event1314
Withdrew: Death15
Withdrew: Investigator decision (includes non-compliance with study drug, investigator determined suitability)22
Withdrew: Site terminated by sponsor at the end of study2716
Withdrew: Withdrawal of consent by subject412
Withdrew: Reason not specified63

Outcome measures

PrimaryOverall Response Rate (ORR)

ORR: Percentage of participants with best overall response of partial response(PR) and complete response(CR). CR criteria: No evidence of new disease; Absolute lymphocyte count(ALC)\<4x10\^9/liter(L); Regression of all target nodal masses to ≤1.5 centimeters(cm) in longest diameter(LD); Normal spleen,liver size; Regression to normal of all nodal non-target disease and disappearance of all detectable; Non-nodal, non-target disease; Morphologically negative bone marrow; No lymphoid nodules; Absolute neutrophil count(ANC)\>1.5x10\^9/L,platelets≥100x10\^9/L,hemoglobin (Hgb)≥110 gram per liter(g/L). PR criteria: No evidence of new disease; Response in 2 of following if abnormal at baseline: ALC\<4x10\^9/L or \>=50% decrease from baseline in sum of products(SPD) of target nodal lesions; splenomegaly; hepatomegaly;\>=50% decrease from baseline in CLL marrow infiltrate/B-lymphoid nodules; response in any 1:ANC\>1.5x10\^9/L,platelets\>100x10\^9/L,Hgb\>110g/L or \>=50% increase over baseline in any of these.

Time frame:
Up to 62 months
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsUblituximab + IbrutinibIbrutinib
Overall Response Rate (ORR)84.469.4
Statistical analysis
  • Ublituximab + Ibrutinib vs Ibrutinib · Cochran-Mantel-Haenszel · p = 0.0463P-value was estimated by Cochran-Mantel-Haenszel (CMH) test stratified by the randomization strata prior lines of therapy.
SecondaryComplete Response (CR) Rate

The CR rate was defined as the percentage of participants who achieved CR. CR criteria: No evidence of new disease; ALC \<4 x 10\^9/L; Regression of all target nodal masses to normal size ≤1.5 cm in the LD; Normal spleen and liver size; Regression to normal of all nodal non-target disease and disappearance of all detectable; Non-nodal, non-target disease; Morphologically negative bone marrow; No lymphoid nodules; ANC \>1.5 x 10\^9/L, platelets ≥100 x 10\^9/L, Hgb ≥110 g/L.

Time frame:
Up to 62 months
Reported as:
Number · percentage of participants
Complete Response (CR) Rate
percentage of participantsUblituximab + IbrutinibIbrutinib
Complete Response (CR) Rate18.84.8
Statistical analysis
  • Ublituximab + Ibrutinib vs Ibrutinib · Cochran-Mantel-Haenszel · p = 0.0159P-value was estimated by CMH test stratified by the randomization strata prior lines of therapy.
SecondaryMinimum Residual Disease (MRD) Negativity Rate

MRD negativity rate was defined as the percentage of participants who were MRD negative post-baseline. If a participant was determined to be MRD negative by peripheral blood, a bone marrow aspirate was obtained to assess MRD in the bone marrow.

Time frame:
Up to 62 months
Reported as:
Number · percentage of participants
Minimum Residual Disease (MRD) Negativity Rate
percentage of participantsUblituximab + IbrutinibIbrutinib
Minimum Residual Disease (MRD) Negativity Rate45.3 (32.8 to 58.3)9.7 (3.6 to 19.9)
Statistical analysis
  • Ublituximab + Ibrutinib vs Ibrutinib · Cochran-Mantel-Haenszel · p = <0.0001 · Rate difference: 35.64 · 95% CI 21.39 to 49.8895% Confidence Interval (CI) was estimated using Clopper-Pearson method based on the binomial distribution.
SecondaryProgression-Free Survival (PFS)

PFS was defined as the time from the date of randomization until the date of first documentation of definitive disease progression (PD) or date of death from any cause, whichever occurs first. PD requires at least one of the following: New nodes \>1.5 cm in the LD and \>1.0 in longest perpendicular diameter (LPD), new or recurrent hepatomegaly or splenomegaly, new or reappearance of an unequivocal extra-nodal lesion, ≥50% increase from the nadir in the sum of products of target lesions, ≥50% increase in the LD of an individual node or extra-nodal mass, splenic/hepatic enlargement of ≥50% from nadir, unequivocal increase in the size of non-target disease, transformation to a more aggressive histology, decrease in platelet count or Hgb, \>50% decrease from the highest on-study platelet count, \>20 g/L decrease from the highest on-study Hgb.

Time frame:
From the randomization until the first documentation of PD or death whichever occurs first or up to 62 months
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsUblituximab + IbrutinibIbrutinib
Progression-Free Survival (PFS)NA (NA to NA)47.2 (18.9 to NA)
Statistical analysis
  • Ublituximab + Ibrutinib vs Ibrutinib · Log Rank · p = 0.0961 · Hazard ratio (hr): 0.573 · 95% CI 0.295 to 1.113Stratified Hazard Ratio and 95% CI were estimated using Cox proportion hazard model and the stratification was based on the randomization strata prior lines of therapy.
SecondaryDuration of Response (DOR)

DOR:Interval from first documentation of CR/PR to first documentation of PD or death from any cause.CR:ALC\<4x10\^9/L;Regression to normal of target nodal masses,nodal non-target disease,and no detectable non-nodal,non-target disease;Normal spleen,liver size;Morphologically negative bone marrow,No lymphoid nodules;ANC\>1.5x10\^9/L,Platelets≥100x10\^9/L,Hgb≥110 g/L.PR:Response in 2 or more:ALC\<4x10\^9/L,\>=50% drop from baseline in ALC or SPD of target nodal lesions,Hepatosplenomegaly,\>=50% decrease from baseline in CLL marrow infiltrate/B-lymphoid nodules;Response in 1 or more:ANC\>1.5x10\^9/L,Platelets\>100x10\^9/L,Hgb\>110 g/L or \>=50% increase over baseline in any.PD:Response in 1 or more:new nodes,Hepatosplenomegaly,unequivocal extra-nodal lesion;≥50% increase from nadir in SPD of target lesions or LD of node/extra-nodal mass or Splenic/Hepatic size,Unequivocal increase in non-target disease,More aggressive histology;Drop of \>50% in platelets/\>20g/L in Hgb from highest on-study count.

Time frame:
From the first dose of study drug until the first documentation of PD or death whichever occurs first or up to 62 months
Reported as:
Median · months
Duration of Response (DOR)
monthsUblituximab + IbrutinibIbrutinib
Duration of Response (DOR)NA (NA to NA)39.1 (16.7 to NA)
Statistical analysis
  • Ublituximab + Ibrutinib vs Ibrutinib · Log Rank · p = 0.1486 · Hazard ratio (hr): 0.569 · 95% CI 0.263 to 1.234Stratified Hazard Ratio and 95% CI were estimated using Cox proportion hazard model and the stratification was based on the randomization strata prior lines of therapy.
SecondaryTime to Response (TTR)

TTR was defined as the interval from the randomization to the first documentation of CR or PR. CR criteria: No evidence of new disease; ALC \<4 x 10\^9/L; Regression of all target nodal masses to normal size ≤1.5 cm in the LD; Normal spleen and liver size; Regression to normal of all nodal non-target disease and disappearance of all detectable; Non-nodal, non-target disease; Morphologically negative bone marrow; No lymphoid nodules; ANC \>1.5 x 10\^9/L, platelets ≥100 x 10\^9/L, Hgb ≥110 g/L. PR criteria: No evidence of new disease; Response in 2 of following when abnormal at baseline: ALC\<4 x 10\^9/L or \>=50% decrease from baseline in SPD of target nodal lesions; splenomegaly; hepatomegaly; \>=50% decrease from baseline in CLL marrow infiltrate/B-lymphoid nodules; and Response in 1 of the following: ANC\>1.5 x 10\^9/L, platelets\>100 x 10\^9/L, Hgb\>110 g/L or \>=50% increase over baseline in any of these.

Time frame:
From the randomization up to 62 months
Reported as:
Median · months
Time to Response (TTR)
monthsUblituximab + IbrutinibIbrutinib
Time to Response (TTR)2.0 (2.0 to 2.1)3.9 (2.2 to 8.3)
Statistical analysis
  • Ublituximab + Ibrutinib vs Ibrutinib · Log Rank · p = 0.0004 · Hazard ratio (hr): 2.163 · 95% CI 1.399 to 3.344Stratified Hazard Ratio and 95% CI were estimated using Cox proportion hazard model and the stratification was based on the randomization strata prior lines of therapy.
SecondaryPercentage of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)

An adverse event (AE) is any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporarily associated with the use of a medicinal product, whether or not considered related to the medicinal product. TEAE is any AE that occur after first dosing of study medication and through the end of the study or through 30 days after the last dose of study treatment, or is considered treatment-related regardless of the start date of the event, or is present before first dosing of study medication but worsens in intensity or the investigator subsequently considers treatment-related.

Time frame:
From the first dose up to 30 days after the last dose of study drug (up to 57.3 months)
Reported as:
Number · percentage of participants
Percentage of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)
percentage of participantsUblituximab + IbrutinibIbrutinib
Percentage of Participants Experiencing at Least One Treatment-Emergent Adverse Event (TEAE)100100

Adverse events

Collected over Adverse Events: From the first dose up to 30 days after the last dose of study drug (up to 57.3 months); All-Cause Mortality: From the first dose up to end of study (up to 62 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ublituximab + Ibrutinib5/59 (8.5%)38/59 (64.4%)59/59 (100%)
Ibrutinib9/58 (15.5%)31/58 (53.4%)57/58 (98.3%)
Most frequent serious events
Showing 10 of 87
Most frequent serious events
EventUblituximab + IbrutinibIbrutinib
PneumoniaInfections and infestations6/594/58
Atrial fibrillationCardiac disorders4/591/58
Febrile neutropeniaBlood and lymphatic system disorders3/591/58
SepsisInfections and infestations3/591/58
Cardiac failureCardiac disorders0/592/58
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/592/58
Squamous cell carcinoma of skinNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/592/58
SyncopeNervous system disorders0/592/58
Mental status changesPsychiatric disorders0/592/58
DyspnoeaRespiratory, thoracic and mediastinal disorders0/592/58
Most frequent other events
Showing 10 of 128
Most frequent other events
EventUblituximab + IbrutinibIbrutinib
DiarrhoeaGastrointestinal disorders34/5926/58
CoughRespiratory, thoracic and mediastinal disorders25/5918/58
NauseaGastrointestinal disorders24/5919/58
FatigueGeneral disorders23/5922/58
Upper respiratory tract infectionInfections and infestations18/5916/58
ArthralgiaMusculoskeletal and connective tissue disorders18/5913/58
HeadacheNervous system disorders18/5917/58
ContusionInjury, poisoning and procedural complications16/5917/58
AnaemiaBlood and lymphatic system disorders17/5912/58
PyrexiaGeneral disorders17/598/58

Baseline characteristics

ITT Population included all randomized participants.

Age, Continuous
Age, Continuous(years)Ublituximab + IbrutinibIbrutinibTotal
Mean67.0 (42 to 86)67.2 (51 to 85)67.1 (42 to 86)
Sex: Female, Male
Sex: Female, Male(Participants)Ublituximab + IbrutinibIbrutinibTotal
Female201636
Male444690
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Ublituximab + IbrutinibIbrutinibTotal
Hispanic or Latino101
Not Hispanic or Latino6259121
Unknown or Not Reported134
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Ublituximab + IbrutinibIbrutinibTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American7613
White5655111
More than one race000
Unknown or Not Reported112
Region of Enrollment
Region of Enrollment(Participants)Ublituximab + IbrutinibIbrutinibTotal
Israel101
United States6362125
08

Study locations

88 sites
  • TG Therapeutics Investigational Trial Site
    Huntsville, Alabama 35805, United States
  • TG Therapeutics Investigational Trial Site
    Mobile, Alabama 36604, United States
  • TG Therapeutics Investigational Trial Site
    Chandler, Arizona 85224, United States
  • TG Therapeutics Investigational Trial Site
    Tucson, Arizona 85710, United States
  • TG Therapeutics Investigational Trial Site
    Fayetteville, Arkansas 72703, United States
  • TG Therapeutics Investigational Trial Site
    Jonesboro, Arkansas 72401, United States
  • TG Therapeutics Investigational Trial Site
    Fullerton, California 92835, United States
  • TG Therapeutics Investigational Trial Site
    Greenbrae, California 94904, United States
  • TG Therapeutics Investigational Trial Site
    Los Angeles, California 90045, United States
  • TG Therapeutics Investigational Trial Site
    Pismo Beach, California 93449, United States
  • TG Therapeutics Investigational Trial Site
    Pleasanton, California 94588, United States
  • TG Therapeutics Investigational Trial Site
    Santa Barbara, California 93105, United States
  • TG Therapeutics Investigational Trial Site
    Aurora, Colorado 80012, United States
  • TG Therapeutics Investigational Trial Site
    Bridgeport, Connecticut 06606, United States
  • TG Therapeutics Investigational Trial Site
    Stamford, Connecticut 06904, United States
  • TG Therapeutics Investigational Trial Site
    Newark, Delaware 19173, United States
  • TG Therapeutics Investigational Trial Site
    Boca Raton, Florida 33486, United States
  • TG Therapeutics Investigational Trial Site
    Fort Myers, Florida 33905, United States
  • TG Therapeutics Investigational Trial Site
    Orange City, Florida 32763, United States
  • TG Therapeutics Investigational Trial Site
    Pensacola, Florida 32504, United States
  • TG Therapeutics Investigational Trial Site
    Saint Petersburg, Florida 33709, United States
  • TG Therapeutics Investigational Trial Site
    West Palm Beach, Florida 33401, United States
  • TG Therapeutics Investigational Trial Site
    Albany, Georgia 31701, United States
  • TG Therapeutics Investigational Trial Site
    Newnan, Georgia 30265, United States
  • TG Therapeutics Investigational Trial Site
    Evanston, Illinois 60201, United States
  • TG Therapeutics Investigational Trial Site
    Maywood, Illinois 60153, United States
  • TG Therapeutics Investigational Trial Site
    Niles, Illinois 60714, United States
  • TG Therapeutics Investigational Trial Site
    Urbana, Illinois 61801, United States
  • TG Therapeutics Investigational Trial Site
    Fort Wayne, Indiana 46804, United States
  • TG Therapeutics Investigational Trial Site
    Indianapolis, Indiana 46237, United States
  • TG Therapeutics Investigational Trial Site
    Ames, Iowa 50010, United States
  • TG Therapeutics Investigational Trial Site
    Cedar Rapids, Iowa 52403, United States
  • TG Therapeutics Investigational Trial Site
    Westwood, Kansas 66205, United States
  • TG Therapeutics Investigational Trial Site
    Baton Rouge, Louisiana 70816, United States
  • TG Therapeutics Investigational Trial Site
    New Orleans, Louisiana 70121, United States
  • TG Therapeutics Investigational Trial Site
    Baltimore, Maryland 21202, United States
  • TG Therapeutics Investigational Trial Site
    Baltimore, Maryland 21215, United States
  • TG Therapeutics Investigational Trial Site
    Bethesda, Maryland 20817, United States
  • TG Therapeutics Investigational Trial Site
    Columbia, Maryland 21044, United States
  • TG Therapeutics Investigational Trial Site
    Salisbury, Maryland 21801, United States
  • TG Therapeutics Investigational Trial Site
    Boston, Massachusetts 02111, United States
  • TG Therapeutics Investigational Trial Site
    Springfield, Massachusetts 01199, United States
  • TG Therapeutics Investigational Trial Site
    Worcester, Massachusetts 01608, United States
  • TG Therapeutics Investigational Trial Site
    Detroit, Michigan 48202, United States
  • TG Therapeutics Investigational Trial Site
    Coon Rapids, Minnesota 55433, United States
  • TG Therapeutics Investigational Trial Site
    Saint Louis Park, Minnesota 55416, United States
  • TG Therapeutics Investigational Trial Site
    Lincoln, Nebraska 68510, United States
  • TG Therapeutics Investigational Trial Site
    Omaha, Nebraska 68130, United States
  • TG Therapeutics Investigational Trial Site
    Lebanon, New Hampshire 03756, United States
  • TG Therapeutics Investigational Trial Site
    East Brunswick, New Jersey 08816, United States
  • TG Therapeutics Investigational Trial Site
    Howell, New Jersey 07731, United States
  • TG Therapeutics Investigational Trial Site
    Morristown, New Jersey 07962, United States
  • TG Therapeutics Investigational Trial Site
    Pompton Plains, New Jersey 07444, United States
  • TG Therapeutics Investigational Trial Site
    Somerville, New Jersey 08876, United States
  • TG Therapeutics Investigational Trial Site
    New York, New York 10019, United States
  • TG Therapeutics Investigational Trial Site
    Syracuse, New York 13210, United States
  • TG Therapeutics Investigational Trial Site
    Charlotte, North Carolina 28204, United States
  • TG Therapeutics Investigational Trial Site
    Durham, North Carolina 27710, United States
  • TG Therapeutics Investigational Trial Site
    Raleigh, North Carolina 27607, United States
  • TG Therapeutics Investigational Trial Site
    Canton, Ohio 44718, United States
  • TG Therapeutics Investigational Trial Site
    Cincinnati, Ohio 45242, United States
  • TG Therapeutics Investigational Trial Site
    Cleveland, Ohio 44106, United States
  • TG Therapeutics Investigational Trial Site
    Portland, Oregon 97213-2982, United States
  • TG Therapeutics Investigational Trial Site
    Portland, Oregon 97227, United States
  • TG Therapeutics Investigational Trial Site
    Springfield, Oregon 97477, United States
  • TG Therapeutics Investigational Trial Site
    Camp Hill, Pennsylvania 17011, United States
  • TG Therapeutics Investigational Trial Site
    Philadelphia, Pennsylvania 19104, United States
  • TG Therapeutics Investigational Trial Site
    Pawtucket, Rhode Island 02860, United States
  • TG Therapeutics Investigational Trial Site
    Greenville, South Carolina 29607, United States
  • TG Therapeutics Investigational Trial Site
    Greenville, South Carolina 29615, United States
  • TG Therapeutics Investigational Trial Site
    Sioux Falls, South Dakota 57105, United States
  • TG Therapeutics Investigational Trial Site
    Watertown, South Dakota 57201, United States
  • TG Therapeutics Investigational Trial Site
    Memphis, Tennessee 38120, United States
  • TG Therapeutics Investigational Trial Site
    Nashville, Tennessee 37203, United States
  • TG Therapeutics Investigational Trial Site
    Austin, Texas 78705, United States
  • TG Therapeutics Investigational Trial Site
    Dallas, Texas 75230, United States
  • TG Therapeutics Investigational Trial Site
    Denton, Texas 76201, United States
  • TG Therapeutics Investigational Trial Site
    Fort Sam Houston, Texas 78234, United States
  • TG Therapeutics Investigational Trial Site
    San Antonio, Texas 78229, United States
  • TG Therapeutics Investigational Trial Site
    Tyler, Texas 75702, United States
  • TG Therapeutics Investigational Trial Site
    Webster, Texas 77598-4420, United States
  • TG Therapeutics Investigational Trial Site
    Ogden, Utah 84403, United States
  • TG Therapeutics Investigational Trial Site
    Blacksburg, Virginia 24060, United States
  • TG Therapeutics Investigational Trial Site
    Richmond, Virginia 23230, United States
  • TG Therapeutics Investigational Trial Site
    Seattle, Washington 98104, United States
  • TG Therapeutics Investigational Trial Site
    Spokane, Washington 99216, United States
  • TG Therapeutics Investigational Trial Site
    Vancouver, Washington 98683, United States
  • TG Therapeutics Investigational Trial Site
    Ashkelon, Israel
09

References and documents

Publications

  • Sharman JP, Brander DM, Mato AR, Ghosh N, Schuster SJ, Kambhampati S, Burke JM, Lansigan F, Schreeder MT, Lunin SD, Zweibach A, Shtivelband M, Travis PM, Chandler JC, Kolibaba KS, Sportelli P, Miskin HP, Weiss MS, Flinn IW. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial. Lancet Haematol. 2021 Apr;8(4):e254-e266. doi: 10.1016/S2352-3026(20)30433-6. Epub 2021 Feb 22. Erratum In: Lancet Haematol. 2021 Apr;8(4):e249. doi: 10.1016/S2352-3026(21)00069-7. PubMed 33631112 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — TG Therapeutics does not currently plan to share IPD.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2015 to primary completion in Apr 2020, 62 months.

Results were first posted in May 2022, 2 years 1 month after primary completion. A results delay was requested in Mar 2021.

Of 57 industry-sponsored phase 3 interventional studies under Leukemia, Lymphocytic, Chronic, B-Cell, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 73. This study's 62 months is above that.

Counting every sponsor, half of 83 studies reached it within 59 months; a quarter within 43 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 20, 2014
First posted
Nov 25, 2014
StartActual
Jan 27, 2015
Primary completionActual
Apr 1, 2020
CompletionActual
Apr 1, 2020
Results delay requested
Mar 23, 2021
Results first posted
May 20, 2022
Last update
May 20, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 20, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02301156
Responsible party
Sponsor
First posted
Nov 25, 2014
Start date
Jan 27, 2015
Primary completion
Apr 1, 2020
Completion
Apr 1, 2020
Results posted
May 20, 2022
Last update
May 20, 2022

Study contacts

Jeff Sharman, MD
study chair · Willamette Valley Cancer Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ublituximab

Start the discussion